These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Histologic Appearance and Immunohistochemistry of DNA Mismatch Repair Protein and p53 in Endometrial Carcinosarcoma: Impact on Prognosis and Insights Into Tumorigenesis. Saijo M; Nakamura K; Ida N; Nasu A; Yoshino T; Masuyama H; Yanai H Am J Surg Pathol; 2019 Nov; 43(11):1493-1500. PubMed ID: 31478942 [TBL] [Abstract][Full Text] [Related]
8. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets. Cimbaluk D; Rotmensch J; Scudiere J; Gown A; Bitterman P Gynecol Oncol; 2007 Apr; 105(1):138-44. PubMed ID: 17175012 [TBL] [Abstract][Full Text] [Related]
9. Molecular events in endometrial carcinosarcomas and the role of high mobility group AT-hook 2 in endometrial carcinogenesis. Romero-Pérez L; Castilla MÁ; López-García MÁ; Díaz-Martín J; Biscuola M; Ramiro-Fuentes S; Oliva E; Matias-Guiu X; Prat J; Cano A; Moreno-Bueno G; Palacios J Hum Pathol; 2013 Feb; 44(2):244-54. PubMed ID: 22974476 [TBL] [Abstract][Full Text] [Related]
10. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison. Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654 [TBL] [Abstract][Full Text] [Related]
11. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus. Kimura F; Watanabe J; Hata H; Fujisawa T; Kamata Y; Nishimura Y; Jobo T; Kuramoto H J Cancer Res Clin Oncol; 2004 Mar; 130(3):161-8. PubMed ID: 14689303 [TBL] [Abstract][Full Text] [Related]
13. Expression profiles of carcinosarcoma of the uterine corpus-are these similar to carcinoma or sarcoma? Chiyoda T; Tsuda H; Tanaka H; Kataoka F; Nomura H; Nishimura S; Takano M; Susumu N; Saya H; Aoki D Genes Chromosomes Cancer; 2012 Mar; 51(3):229-39. PubMed ID: 22072501 [TBL] [Abstract][Full Text] [Related]
14. CD34 immunohistochemistry in female genital tract carcinosarcoma (malignant mixed müllerian tumors) supports a dominant role of the carcinomatous component. Costa MJ; Guinee D Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):293-9. PubMed ID: 11127921 [TBL] [Abstract][Full Text] [Related]
15. Overexpression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in uterine carcinosarcomas. Santin AD; Bellone S; Siegel ER; McKenney JK; Thomas M; Roman JJ; Burnett A; Tognon G; Bandiera E; Pecorelli S Clin Cancer Res; 2007 Jun; 13(11):3339-46. PubMed ID: 17545541 [TBL] [Abstract][Full Text] [Related]
16. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232 [TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical study of DNA topoisomerase I, p53, and Ki-67 in uterine carcinosarcomas. Lee SJ; Kim HS; Kim HS; Chun YK; Hong SR; Lee JH Hum Pathol; 2007 Aug; 38(8):1226-31. PubMed ID: 17490723 [TBL] [Abstract][Full Text] [Related]
18. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma. Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476 [TBL] [Abstract][Full Text] [Related]
19. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Livasy CA; Reading FC; Moore DT; Boggess JF; Lininger RA Gynecol Oncol; 2006 Jan; 100(1):101-6. PubMed ID: 16157366 [TBL] [Abstract][Full Text] [Related]